Ubs Group Ag Crinetics Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

$452 Billion
Q3 2024

A detailed history of Ubs Group Ag transactions in Crinetics Pharmaceuticals, Inc. stock. As of the latest transaction made, Ubs Group Ag holds 182,886 shares of CRNX stock, worth $9.27 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

182,886

Previous 182,942 0.03%

Holding current value

$9.27 Million

Previous $8.19 Million 14.01%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$43.83 - $54.98 $2,454 - $3,078	-56 Reduced 0.03%	182,886 $9.34 Million
Q2 2024 Aug 13, 2024	SELL	$42.12 - $51.91 $2.73 Million - $3.37 Million	-64,861 Reduced 26.17%	182,942 $8.19 Million
Q1 2024 May 13, 2024	BUY	$34.76 - $46.81 $3.8 Million - $5.12 Million	109,338 Added 78.96%	247,803 $11.6 Million
Q4 2023 Feb 09, 2024	BUY	$25.62 - $37.07 $1.45 Million - $2.1 Million	56,607 Added 69.15%	138,465 $4.93 Million
Q3 2023 Nov 09, 2023	SELL	$15.97 - $30.59 $1.02 Million - $1.95 Million	-63,835 Reduced 43.81%	81,858 $2.43 Million
Q2 2023 Aug 11, 2023	BUY	$15.73 - $23.6 $1.36 Million - $2.04 Million	86,525 Added 146.24%	145,693 $2.63 Million
Q1 2023 May 12, 2023	SELL	$15.31 - $21.1 $329,563 - $454,198	-21,526 Reduced 26.68%	59,168 $950,000
Q4 2022 Feb 08, 2023	BUY	$15.49 - $19.05 $1.12 Million - $1.38 Million	72,555 Added 891.45%	80,694 $1.48 Million
Q3 2022 Nov 10, 2022	SELL	$18.11 - $22.37 $199,952 - $246,987	-11,041 Reduced 57.57%	8,139 $160,000
Q2 2022 Aug 10, 2022	SELL	$16.49 - $27.64 $813,171 - $1.36 Million	-49,313 Reduced 72.0%	19,180 $358,000
Q1 2022 May 16, 2022	BUY	$17.15 - $28.31 $268,791 - $443,702	15,673 Added 29.67%	68,493 $1.5 Million
Q4 2021 Feb 14, 2022	BUY	$19.35 - $28.41 $611,324 - $897,557	31,593 Added 148.83%	52,820 $1.5 Million
Q3 2021 Nov 15, 2021	BUY	$16.88 - $25.23 $358,311 - $535,557	21,227 New	21,227 $447,000
Q2 2021 Aug 13, 2021	SELL	$15.9 - $21.15 $65,651 - $87,328	-4,129 Closed	0 $0
Q1 2021 May 12, 2021	BUY	$13.3 - $17.55 $26,999 - $35,626	2,030 Added 96.71%	4,129 $63,000
Q4 2020 Feb 11, 2021	BUY	$12.08 - $17.46 $25,355 - $36,648	2,099 New	2,099 $30,000
Q3 2020 Nov 12, 2020	SELL	$13.62 - $17.66 $123,846 - $160,582	-9,093 Closed	0 $0
Q2 2020 Jul 31, 2020	BUY	$13.04 - $23.23 $11,436 - $20,372	877 Added 10.67%	9,093 $159,000
Q1 2020 May 01, 2020	SELL	$11.52 - $26.46 $102,193 - $234,726	-8,871 Reduced 51.92%	8,216 $121,000
Q4 2019 Feb 14, 2020	BUY	$15.24 - $25.09 $120,213 - $197,909	7,888 Added 85.75%	17,087 $429,000
Q3 2019 Nov 14, 2019	BUY	$14.91 - $25.01 $126,943 - $212,935	8,514 Added 1242.92%	9,199 $138,000
Q2 2019 Aug 14, 2019	SELL	$21.48 - $27.71 $917,861 - $1.18 Million	-42,731 Reduced 98.42%	685 $17,000
Q1 2019 May 14, 2019	BUY	$21.07 - $29.31 $902,238 - $1.26 Million	42,821 Added 7196.81%	43,416 $988,000
Q4 2018 Feb 14, 2019	SELL	$22.4 - $35.39 $23,340 - $36,876	-1,042 Reduced 63.65%	595 $18,000
Q3 2018 Nov 14, 2018	BUY	$22.66 - $36.8 $37,094 - $60,241	1,637 New	1,637 $47,000

Others Institutions Holding CRNX

# of Institutions

241

Shares Held

79.5M

Call Options Held

23.3K

Put Options Held

44.3K

View Full List

About Crinetics Pharmaceuticals, Inc.

Ticker CRNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 53,752,800
Market Cap $2.72B
Description
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III ...

More about CRNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Group Ag with notifications on news.

Account